Future research should focus on (1) exploring the potential of RAC2 inhibitors like NSC-23766 and EHT1864 in diverse cancer models, (2) assessing the prognostic significance of PTTG1 expression in clinical cohorts, and (3) conducting mechanistic studies to determine whether RAC2 and PTTG1 interact directly or operate independently through parallel pathways. This evidence concerns the gene PTTG1 and cancer.